Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 393

1.

Growth inhibition of human multiple myeloma cells by an oncolytic adenovirus carrying the CD40 ligand transgene.

Fernandes MS, Gomes EM, Butcher LD, Hernandez-Alcoceba R, Chang D, Kansopon J, Newman J, Stone MJ, Tong AW.

Clin Cancer Res. 2009 Aug 1;15(15):4847-56. doi: 10.1158/1078-0432.CCR-09-0451. Epub 2009 Jul 21.

2.

Antitumor activity of an oncolytic adenoviral-CD40 ligand (CD154) transgene construct in human breast cancer cells.

Gomes EM, Rodrigues MS, Phadke AP, Butcher LD, Starling C, Chen S, Chang D, Hernandez-Alcoceba R, Newman JT, Stone MJ, Tong AW.

Clin Cancer Res. 2009 Feb 15;15(4):1317-25. doi: 10.1158/1078-0432.CCR-08-1360.

3.

Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer.

Tong AW, Papayoti MH, Netto G, Armstrong DT, Ordonez G, Lawson JM, Stone MJ.

Clin Cancer Res. 2001 Mar;7(3):691-703.

4.

Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus.

Diaconu I, Cerullo V, Hirvinen ML, Escutenaire S, Ugolini M, Pesonen SK, Bramante S, Parviainen S, Kanerva A, Loskog AS, Eliopoulos AG, Pesonen S, Hemminki A.

Cancer Res. 2012 May 1;72(9):2327-38. doi: 10.1158/0008-5472.CAN-11-2975. Epub 2012 Mar 6.

5.

Adenovector-induced expression of human-CD40-ligand (hCD40L) by multiple myeloma cells. A model for immunotherapy.

Dotti G, Savoldo B, Takahashi S, Goltsova T, Brown M, Rill D, Rooney C, Brenner M.

Exp Hematol. 2001 Aug;29(8):952-61.

PMID:
11495701
6.

A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.

Hu ZB, Wu CT, Wang H, Zhang QW, Wang L, Wang RL, Lu ZZ, Wang LS.

Cancer Gene Ther. 2008 Mar;15(3):173-82. Epub 2007 Dec 21.

PMID:
18157145
8.

CD40 ligand-induced apoptosis is Fas-independent in human multiple myeloma cells.

Tong AW, Seamour B, Chen J, Su D, Ordonez G, Frase L, Netto G, Stone MJ.

Leuk Lymphoma. 2000 Feb;36(5-6):543-58.

PMID:
10784400
10.

Reexpression of human somatostatin receptor gene 2 gene mediated by oncolytic adenovirus increases antitumor activity of tumor necrosis factor-related apoptosis-inducing ligand against pancreatic cancer.

Zhang Z, Huang Y, Newman K, Gu J, Zhang X, Wu H, Zhao M, Xianyu Z, Liu X.

Clin Cancer Res. 2009 Aug 15;15(16):5154-60. doi: 10.1158/1078-0432.CCR-09-0025. Epub 2009 Aug 11.

11.
12.

Inhibition of retinoblastoma in vitro and in vivo with conditionally replicating oncolytic adenovirus H101.

Song X, Zhou Y, Jia R, Xu X, Wang H, Hu J, Ge S, Fan X.

Invest Ophthalmol Vis Sci. 2010 May;51(5):2626-35. doi: 10.1167/iovs.09-3516. Epub 2009 Dec 10.

PMID:
20007825
13.

Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.

Zhang Q, Chen G, Peng L, Wang X, Yang Y, Liu C, Shi W, Su C, Wu H, Liu X, Wu M, Qian Q.

Clin Cancer Res. 2006 Nov 1;12(21):6523-31.

14.

Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus.

Liu TC, Wang Y, Hallden G, Brooks G, Francis J, Lemoine NR, Kirn D.

Gene Ther. 2005 Sep;12(17):1333-46.

PMID:
15920462
15.

Adenovirus delivery of human CD40 ligand gene confers direct therapeutic effects on carcinomas.

Vardouli L, Lindqvist C, Vlahou K, Loskog AS, Eliopoulos AG.

Cancer Gene Ther. 2009 Nov;16(11):848-60. doi: 10.1038/cgt.2009.31. Epub 2009 May 22.

PMID:
19461675
16.

A novel triple-regulated oncolytic adenovirus carrying PDCD5 gene exerts potent antitumor efficacy on common human leukemic cell lines.

Xie M, Niu JH, Chang Y, Qian QJ, Wu HP, Li LF, Zhang Y, Li JL, Huang XJ, Ruan GR.

Apoptosis. 2009 Sep;14(9):1086-94. doi: 10.1007/s10495-009-0373-3.

PMID:
19551515
17.
18.

E1B 55-kDa deleted, Ad5/F35 fiber chimeric adenovirus, a potential oncolytic agent for B-lymphocytic malignancies.

Wang G, Li G, Liu H, Yang C, Yang X, Jin J, Liu X, Qian Q, Qian W.

J Gene Med. 2009 Jun;11(6):477-85. doi: 10.1002/jgm.1326.

PMID:
19340843
19.

Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma.

Lamfers ML, Gianni D, Tung CH, Idema S, Schagen FH, Carette JE, Quax PH, Van Beusechem VW, Vandertop WP, Dirven CM, Chiocca EA, Gerritsen WR.

Cancer Res. 2005 Oct 15;65(20):9398-405.

20.

Short hairpin RNA-expressing oncolytic adenovirus-mediated inhibition of IL-8: effects on antiangiogenesis and tumor growth inhibition.

Yoo JY, Kim JH, Kim J, Huang JH, Zhang SN, Kang YA, Kim H, Yun CO.

Gene Ther. 2008 May;15(9):635-51. doi: 10.1038/gt.2008.3. Epub 2008 Feb 14.

PMID:
18273054

Supplemental Content

Support Center